Chronic Kidney Disease Trial, Recruiting NCT06598436 Sponsor: University of California, San Francisco Condition: Chronic Kidney Disease
Back to Chronic Kidney Disease

Chronic Kidney Disease Trial, Recruiting

NCT06598436
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who speak English or Spanish
  • People who have been diagnosed with diabetes and have had a blood sugar control test (called an A1C) result of 8.0% or higher in the past two years, OR people who have been diagnosed with high blood pressure and have had a recorded top blood pressure reading above 140 mmHg
  • People who have had at least 2 visits at a participating San Francisco Health Network (SFHN) primary care clinic in the last 24 months

Who may not be able to join:

  • People who already have a higher-than-average ability to use digital health tools, as measured by a specific digital health literacy score (confirm with trial site)
  • People who have serious health conditions that would make it unsuitable to focus on managing long-term illness through telehealth, such as a terminal illness with a short life expectancy, or a severe mental illness
  • People who do not have any working phone number
  • People whose vision or hearing difficulties would prevent them from using telehealth services for managing a long-term condition
  • People who have difficulty with memory or thinking that makes it hard to understand and restate the goals of the study during the consent process
  • People who are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Delphine Tuot, MD MAS, University of California, San Francisco

Phone: 415-562-4509

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
4 November 2024
Est. completion
1 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Patient-Level Hemoglobin A1C; Change in Patient Portal Use

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov